Loading...

Immune Design

DB:6ID
Snowflake Description

Flawless balance sheet and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
6ID
DB
$283M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Immune Design Corp., a clinical-stage immunotherapy company, focuses on cancer with in vivo approaches to enable the body’s immune system to fight disease. The last earnings update was 20 days ago. More info.


Add to Portfolio Compare Print
  • Immune Design has significant price volatility in the past 3 months.
6ID Share Price and Events
7 Day Returns
1%
DB:6ID
3.5%
DE Biotechs
2.3%
DE Market
1 Year Returns
106.3%
DB:6ID
-10.3%
DE Biotechs
-7.1%
DE Market
6ID Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Immune Design (6ID) 1% 1.8% 348.3% 106.3% - -
DE Biotechs 3.5% -5% 0.5% -10.3% 51.9% 4.7%
DE Market 2.3% 0.5% 9.3% -7.1% 10% 9.9%
1 Year Return vs Industry and Market
  • 6ID outperformed the Biotechs industry which returned -10.3% over the past year.
  • 6ID outperformed the Market in Germany which returned -7.1% over the past year.
Price Volatility
6ID
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Immune Design undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Immune Design to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Immune Design.

DB:6ID Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:6ID
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.454 (1 + (1- 21%) (0%))
1.304
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.304 * 5.96%)
8%

Discounted Cash Flow Calculation for DB:6ID using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Immune Design is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:6ID DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8%)
2019 -43.60 Analyst x1 -40.37
2020 -48.50 Analyst x1 -41.58
2021 5.00 Analyst x1 3.97
2022 14.90 Analyst x1 10.95
2023 25.20 Analyst x1 17.15
2024 34.29 Est @ 36.05% 21.61
2025 42.96 Est @ 25.31% 25.07
2026 50.60 Est @ 17.78% 27.34
2027 56.93 Est @ 12.52% 28.48
2028 61.96 Est @ 8.83% 28.70
Present value of next 10 years cash flows $81.32
DB:6ID DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $61.96 × (1 + 0.23%) ÷ (8% – 0.23%)
$799.11
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $799.11 ÷ (1 + 8%)10
$370.17
DB:6ID Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $81.32 + $370.17
$451.49
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $451.49 / 48.37
$9.33
DB:6ID Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:6ID represents 0.88889x of NasdaqGM:IMDZ
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.88889x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 9.33 x 0.88889
€8.30
Value per share (EUR) From above. €8.30
Current discount Discount to share price of €5.20
= -1 x (€5.20 - €8.30) / €8.30
37.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Immune Design is available for.
Intrinsic value
37%
Share price is €5.2 vs Future cash flow value of €8.3
Current Discount Checks
For Immune Design to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Immune Design's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Immune Design's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Immune Design's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Immune Design's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:6ID PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.14
NasdaqGM:IMDZ Share Price ** NasdaqGM (2019-04-02) in USD $5.85
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 23.36x
Germany Market PE Ratio Median Figure of 423 Publicly-Listed Companies 19.12x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Immune Design.

DB:6ID PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:IMDZ Share Price ÷ EPS (both in USD)

= 5.85 ÷ -1.14

-5.14x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Immune Design is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Immune Design is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Immune Design's expected growth come at a high price?
Raw Data
DB:6ID PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.14x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
-2.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 21 Publicly-Listed Biotechs Companies 1.22x
Germany Market PEG Ratio Median Figure of 272 Publicly-Listed Companies 1.47x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Immune Design, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Immune Design's assets?
Raw Data
DB:6ID PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $1.91
NasdaqGM:IMDZ Share Price * NasdaqGM (2019-04-02) in USD $5.85
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.43x
Germany Market PB Ratio Median Figure of 571 Publicly-Listed Companies 1.79x
DB:6ID PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:IMDZ Share Price ÷ Book Value per Share (both in USD)

= 5.85 ÷ 1.91

3.07x

* Primary Listing of Immune Design.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Immune Design is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Immune Design's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Immune Design has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Immune Design expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-2.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Immune Design expected to grow at an attractive rate?
  • Unable to compare Immune Design's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Immune Design's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Immune Design's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:6ID Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:6ID Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts -2.6%
DB:6ID Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 63.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 49.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 27.9%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:6ID Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:6ID Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 67 25 -40 4
2022-12-31 36 15 -79 3
2021-12-31 5 5 -84 4
2020-12-31 3 -49 -71 3
2019-12-31 2 -44 -62 3
DB:6ID Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 2 -52 -55
2018-09-30 2 -56 -53
2018-06-30 2 -61 -53
2018-03-31 2 -58 -53
2017-12-31 7 -47 -52
2017-09-30 9 -41 -54
2017-06-30 16 -35 -53
2017-03-31 17 -35 -54
2016-12-31 13 -36 -54
2016-09-30 12 -39 -51
2016-06-30 9 -37 -46
2016-03-31 9 -35 -42

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Immune Design is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Immune Design's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:6ID Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Immune Design Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:6ID Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.90 -0.27 -1.51 3.00
2022-12-31 -1.12 -0.85 -1.38 3.00
2021-12-31 -1.24 -1.03 -1.35 3.00
2020-12-31 -1.15 -0.87 -1.42 4.00
2019-12-31 -1.15 -1.06 -1.37 4.00
DB:6ID Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.14
2018-09-30 -1.14
2018-06-30 -1.28
2018-03-31 -1.49
2017-12-31 -1.75
2017-09-30 -2.13
2017-06-30 -2.19
2017-03-31 -2.35
2016-12-31 -2.47
2016-09-30 -2.52
2016-06-30 -2.29
2016-03-31 -2.12

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Immune Design will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Immune Design's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Immune Design has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Immune Design performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Immune Design's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Immune Design does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Immune Design's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Immune Design's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Immune Design's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Immune Design Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:6ID Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 2.20 -54.76 16.15
2018-09-30 2.21 -53.14 16.87
2018-06-30 2.26 -52.50 16.23
2018-03-31 2.23 -52.54 16.11
2017-12-31 7.20 -51.86 16.25
2017-09-30 8.77 -54.33 16.33
2017-06-30 16.46 -53.36 16.12
2017-03-31 16.86 -53.86 16.18
2016-12-31 13.26 -53.53 15.96
2016-09-30 12.34 -51.20 15.61
2016-06-30 8.79 -46.16 15.42
2016-03-31 9.44 -42.33 15.25
2015-12-31 9.51 -39.45 15.13
2015-09-30 10.17 -40.45 16.64
2015-06-30 9.06 -39.73 17.21
2015-03-31 8.35 -35.33 15.28
2014-12-31 6.43 -34.15 12.93
2014-09-30 4.66 -26.44 8.98 2.74
2014-06-30 1.24 -23.75 6.03 5.66
2014-03-31 1.06 -21.26 5.10 9.01
2013-12-31 1.60 -15.98 4.43
2012-12-31 2.96 -10.84 3.71 8.60

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Immune Design has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Immune Design has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Immune Design improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Immune Design's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Immune Design has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Immune Design's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Immune Design's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Immune Design is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Immune Design's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Immune Design's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Immune Design has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Immune Design Company Filings, last reported 3 months ago.

DB:6ID Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 92.01 0.00 95.89
2018-09-30 104.49 0.00 107.39
2018-06-30 116.72 0.00 120.23
2018-03-31 128.86 0.00 130.88
2017-12-31 139.21 0.00 141.11
2017-09-30 62.59 0.00 64.34
2017-06-30 73.54 0.00 81.28
2017-03-31 85.07 0.00 89.91
2016-12-31 95.18 0.00 107.26
2016-09-30 107.26 0.00 112.47
2016-06-30 87.06 0.00 92.59
2016-03-31 99.05 0.00 100.83
2015-12-31 108.99 0.00 112.92
2015-09-30 119.17 0.00 120.49
2015-06-30 125.08 0.00 129.00
2015-03-31 58.25 0.00 60.23
2014-12-31 66.35 0.00 75.35
2014-09-30 79.00 0.00 83.39
2014-06-30 19.15 0.00 18.00
2014-03-31 23.57 0.00 25.02
2013-12-31 28.90 0.00 30.39
2012-12-31 11.61 0.00 12.76
  • Immune Design has no debt.
  • Immune Design has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Immune Design has sufficient cash runway for 1.8 years based on current free cash flow.
  • Immune Design has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 18.7% each year.
X
Financial health checks
We assess Immune Design's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Immune Design has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Immune Design's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Immune Design dividends.
If you bought €2,000 of Immune Design shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Immune Design's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Immune Design's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:6ID Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:6ID Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Immune Design has not reported any payouts.
  • Unable to verify if Immune Design's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Immune Design's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Immune Design has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Immune Design's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Immune Design afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Immune Design has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Immune Design's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Carlos Paya
COMPENSATION $2,010,997
AGE 59
TENURE AS CEO 7.9 years
CEO Bio

Dr. Carlos V. Paya, M.D., Ph.D. has been the Chief Executive Officer and President of Immune Design Corp. since May 2, 2011. Dr. Paya served as the President at Elan Corp. plc since November 25, 2008 until 2011. Dr. Paya led the Biotechnology commercial, marketing, clinical, research and development teams since 2008. Before joining Elan Corporation, Dr. Paya was at Eli Lilly & Company, a pharmaceutical corporation, from September 2001 to November 2008, as Vice President, Lilly Research Laboratories and Global Leader of the Diabetes and Endocrine Platform, responsible for its dominant franchise (insulin products). He served as an Executive with Lilly since 2001, gaining a wide range of leadership experience in different therapeutic areas and business strategy. His therapeutic responsibilities have included infectious disease, inflammation, women's health and pulmonary; and his management responsibilities have included regulatory, joint venture relationships, pharmaco-economics, brand development and product positioning. Dr. Paya has over 15 years of senior executive experience in the large, mid-cap and small-cap biopharmaceutical industries, combined with a prolific scientific background and a track record of leading high-impact innovation. Prior to his Executive career at Lilly, Dr. Paya had a unique, 16-year relationship with the Mayo Clinic in Rochester, Minnesota, which began with his acceptance into the Mayo Graduate School of Medicine in 1984. He served as Vice Dean of the Clinical Investigation program at Mayo ClinInc. for 6 years. Dr. Paya's other responsibilities and positions with Mayo included two years as Senior Associate Consulting Staff, Infectious Diseases and Internal Medicine, Pathology and Laboratory Medicine and Immunology; and four years as a Research Scientist at Institute Pasteur, Paris and as Chief, Infectious Diseases Unit, Hospital 12 Octubre, Madrid, Spain. Dr. Paya was assisted in the search and hiring process for the position by Heidrick & Struggles. Dr. Paya has been a Director of Immune Design Corp. since May 2, 2011. He has been Director at Fluidigm Corporation since March 2017. From January 1991 to August 2001, Dr. Paya was a Professor of Medicine, Immunology and Pathology at Mayo Clinic for 6 years. He was Associate Professor of Mayo for 2 years. He received his M.D. and Ph.D. degrees from the University of Madrid and underwent postdoctoral training at the Institute Pasteur in Paris.

CEO Compensation
  • Carlos's compensation has been consistent with company performance over the past year.
  • Carlos's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Immune Design management team in years:

5.5
Average Tenure
55
Average Age
  • The average tenure for the Immune Design management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Carlos Paya

TITLE
CEO, President & Director
COMPENSATION
$2M
AGE
59
TENURE
7.9 yrs

Steve Brady

TITLE
Executive Vice President of Strategy & Finance
COMPENSATION
$1M
AGE
48
TENURE
3.9 yrs

Jan Ter Meulen

TITLE
Chief Scientific Officer
COMPENSATION
$951K
AGE
55
TENURE
5.5 yrs

Sylvia Wheeler

TITLE
Investor Relations Officer

Wayne Gombotz

TITLE
Chief Development Officer
COMPENSATION
$497K
AGE
59
TENURE
7.3 yrs

Frank Hsu

TITLE
Head of Oncology & Vice President
TENURE
5.5 yrs

Sergey Yurasov

TITLE
Senior VP of Clinical Development & Chief Medical Officer
AGE
49
TENURE
2.5 yrs
Board of Directors Tenure

Average tenure and age of the Immune Design board of directors in years:

5.7
Average Tenure
71
Average Age
  • The tenure for the Immune Design board of directors is about average.
Board of Directors

Ed Penhoet

TITLE
Chairman of the Board
COMPENSATION
$112K
AGE
77
TENURE
6.3 yrs

Carlos Paya

TITLE
CEO, President & Director
COMPENSATION
$2M
AGE
59
TENURE
7.9 yrs

Rafi Ahmed

TITLE
Chairman of Scientific Advisory Board

David Baltimore

TITLE
Director & Member of Scientific Advisory Board
COMPENSATION
$87K
AGE
80

Bill Ringo

TITLE
Director
COMPENSATION
$101K
AGE
73
TENURE
5.2 yrs

Franklin Berger

TITLE
Director
COMPENSATION
$104K
AGE
69
TENURE
5.1 yrs

Steve Reed

TITLE
Co-founder & Member of Scientific Advisory Board
AGE
67

Larry Corey

TITLE
Member of Scientific Advisory Board

Phil Greenberg

TITLE
Member of Scientific Advisory Board

Carl June

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
05. Dec 18 Sell BVF Partners LP Company 04. Dec 18 04. Dec 18 -902,000 €1.61 €-1,456,596
X
Management checks
We assess Immune Design's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Immune Design has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Immune Design Corp., a clinical-stage immunotherapy company, focuses on cancer with in vivo approaches to enable the body’s immune system to fight disease. The company develops products based on its ZVex and GLAAS discovery platforms. Its lead product candidate is G100, a monotherapy and combination therapy that is in Phase II clinical trials for treating patients with follicular non-Hodgkin lymphoma. The company has collaboration and license agreements with Sanofi Pasteur. Immune Design Corp. was founded in 2008 and is headquartered in Seattle, Washington.

Details
Name: Immune Design Corp.
6ID
Exchange: DB
Founded: 2008
$252,917,116
48,365,248
Website: http://www.immunedesign.com
Address: Immune Design Corp.
1616 Eastlake Avenue East,
Suite 310,
Seattle,
Washington, 98102,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM IMDZ Common Stock Nasdaq Global Market US USD 24. Jul 2014
DB 6ID Common Stock Deutsche Boerse AG DE EUR 24. Jul 2014
Number of employees
Current staff
Staff numbers
49
Immune Design employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/02 22:21
End of day share price update: 2019/04/02 00:00
Last estimates confirmation: 2019/04/02
Last earnings filing: 2019/03/13
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.